<SEC-DOCUMENT>0001193125-15-246005.txt : 20150707
<SEC-HEADER>0001193125-15-246005.hdr.sgml : 20150707
<ACCEPTANCE-DATETIME>20150707063459
ACCESSION NUMBER:		0001193125-15-246005
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150707
FILED AS OF DATE:		20150707
DATE AS OF CHANGE:		20150707

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Prima BioMed Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		15975288

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 7, 151 MACQUARIE STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 7, 151 MACQUARIE STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d18814d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13A-16</FONT> OR
<FONT STYLE="white-space:nowrap">15D-16</FONT> UNDER THE </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated July 7, 2015 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">001-35428</FONT> </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>P<SMALL>RIMA</SMALL> B<SMALL>IO</SMALL>M<SMALL>ED</SMALL> L<SMALL>TD</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of Registrant&#146;s Name) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 7, 151 Macquarie Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Sydney, 2000 New South Wales, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by
check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT STYLE="white-space:nowrap">40-F.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
<FONT STYLE="white-space:nowrap">20-F&nbsp;&nbsp;</FONT><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form <FONT STYLE="white-space:nowrap">40-F&nbsp;&nbsp;</FONT><FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b) (1):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by
Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b) (7):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;
&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2(b): Not applicable. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: July 7, 2015 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>Prima BioMed Ltd</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:75.45pt; font-size:8pt; font-family:Times New Roman"><B>Description of Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Prima Biomed Receives Positive Scientific Advice From The European Medicines Agency For It&#146;s Lead Product, IMP321</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d18814dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g18814img001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7&nbsp;July 2015 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRIMA BIOMED RECEIVES
POSITIVE SCIENTIFIC ADVICE </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FROM THE EUROPEAN MEDICINES AGENCY FOR ITS LEAD PRODUCT, IMP321 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The EMA has now confirmed in writing its endorsement of the development program of IMP321 in metastatic breast cancer. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (&#147;Prima&#148; or the &#147;Company&#148;), a leading immuno-oncology company, is pleased to
announce that it has received positive Scientific Advice from the European Medicines Agency (&#147;EMA&#148; or the &#147;Agency&#148;) on the development path for its lead product, IMP321 in metastatic breast cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The EMA, located in London, is the agency responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in the European
Union. After dialogue between Prima and the EMA, the Agency has now confirmed in writing its endorsement of the development program of IMP321 in metastatic breast cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Encouragingly, the planned Phase IIb study, to be called AIPAC (<U>A</U>ctive <U>I</U>mmunotherapy <U>PAC</U>litaxel) is considered well designed by the
Agency. AIPAC is now expected to initiate in Europe during the 4th quarter of 2015. While the EMA never endorses any statement on the likelihood of future regulatory decisions, the Agency&#146;s communication has suggested that the achievement of
certain clinical endpoints may lead to Marketing Authorization in the EU based on this one pivotal study. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After a smaller safety run-in phase that will
extend into 2016 and will yield valuable safety, pharmacokinetic and pharmacodynamic data, AIPAC will proceed to recruit around 200 patients with HER-2 negative metastatic breast cancer, randomising them 1:1 to either standard-of-care paclitaxel
plus placebo or paclitaxel plus IMP321. The trial will have Progression-Free Survival as its Primary Endpoint, with response rates according to the RECIST criteria and Overall Survival among the secondary endpoints. The study has been powered to
show a four-month PFS advantage for the treatment group<SUP STYLE="font-size:85%; vertical-align:top">1</SUP>. Allowing time for patient recruitment and follow-up, AIPAC&#146;s expected duration is around three years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima&#146;s Chief Scientific and Medical Officer, Professor Fr&eacute;d&eacute;ric Triebel, stated, &#147;The EMA&#146;s Scientific Advice represents a
significant step forward in terms of IMP321 clinical development in Europe. We now have the opportunity to introduce active immunotherapy to metastatic breast cancer patients, a promising novel strategy that we believe has the potential to fulfil an
unmet medical need.&#148; Dr.&nbsp;Triebel added, &#147;We wish to thank the EMA&#146;s Scientific Advice Working Party for their input and guidance.&#148; </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In HER2-negative metastatic breast cancer PFS can be as low as 6 months - see Miller et. al., N Engl J Med. 2007 Dec 27; 357(26):2666-76. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prima BioMed Ltd</B>,
Level 7, 151 Macquarie Street, Sydney NSW 2000 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Phone: +61 2 9276 1224 Fax: +61 2 8569 1880 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">www.primabiomed.com.au &nbsp;&nbsp;&nbsp;&nbsp;ABN: 90 009 237 889 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Scientific Advice </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scientific Advice is a procedure offered by the EMA to pharmaceutical industry participants for clarification of questions arising during development of
medicinal products. Scientific Advice is prospective in nature and it focuses on development strategies rather than pre-evaluation of data to support a Marketing Authorisation Application (MAA). Scientific Advice is legally non-binding and is based
on the current scientific knowledge which may be subject to future changes. Nevertheless, the advice provided is taken into consideration during MAA and any deviations from the advice given need to be well justified. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About AIPAC (<U>A</U>ctive <U>I</U>mmunotherapy <U>PAC</U>litaxel</B>) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AIPAC is the acronym for Prima&#146;s planned multicenter, Phase IIb, randomized, double blinded, placebo-controlled clinical trial in HER-2 negative
metastatic breast cancer patients receiving IMP321 or placebo as adjunctive to the standard-of-care chemotherapy drug paclitaxel. In a Phase IIa trial, IMP321 was able to increase the response rate (as per the RECIST criteria) at six months in these
patients from the 25% expected of paclitaxel<SUP STYLE="font-size:85%; vertical-align:top">2</SUP> to 50% for IMP321 plus paclitaxel<SUP STYLE="font-size:85%; vertical-align:top">3</SUP>. The primary purpose of the AIPAC trial is to determine the
clinical benefit of IMP321 in terms of Progression-Free Survival in this patient population (power 80%). Details of the AIPC study will be posted on <U>www.clinicaltrials.gov</U> in due course. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About IMP321 and cancer immunotherapy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IMP321 is a cancer
immunotherapy agent currently in mid-stage clinical development with Prima BioMed, where it is the company&#146;s lead compound. Immunotherapy is a process whereby a disease such as cancer is treated either by activating or suppressing components of
the immune system to generate a response. LAG-3, or Lymphocyte Activation Gene 3, is able to stimulate and in other cases inhibit an immune response, through involvement in a number of immune pathways. IMP321 is a soluble LAG-3Ig fusion protein
which works by binding to MHC class II molecules on APCs such as dendritic cells to activate them. The APCs are important for showing cancer antigens to T cells and activating them to destroy cancer cells. IMP321 is a first-in-class APC activator.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Prima BioMed </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima BioMed is a globally
active biotechnology company that is striving to become a leader in the development of immunotherapeutic products for the treatment of cancer. Prima BioMed is dedicated to leveraging its technology and expertise to bring innovative treatment options
to market for patients and to maximise value to shareholders.</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See Gray et. al., J Clin Oncol. 2009 Oct 20; 27(30): 4966&#150;4972. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See Brignone et.al., J Transl Med. 2010 Jul 23;8:71. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prima BioMed Ltd</B>,
Level 7, 151 Macquarie Street, Sydney NSW 2000 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Phone: +61 2 9276 1224 Fax: +61 2 8569 1880 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">www.primabiomed.com.au &nbsp;&nbsp;&nbsp;&nbsp;ABN: 90 009 237 889 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima&#146;s original product, called CVac, is an <I>ex vivo</I> dendritic cell priming therapy that in May 2015
yielded favourable Phase II data in second remission ovarian cancer patients. Prima is currently seeking partners for further development of this therapy. Prima&#146;s current lead product is IMP321, based on the LAG-3 immune control mechanism which
plays a vital role in the regulation of the T cell immune response. IMP321, which is soluble LAG-3, is a T cell immunostimulatory factor for cancer chemoimmunotherapy which has completed early Phase II trials. A number of additional LAG-3 products
including antibodies for immune response modulation in autoimmunity and cancer are being developed by large pharmaceutical partners.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima BioMed is
listed on the Australian Stock Exchange, on the NASDAQ in the US. For further information please visit <U>www.primabiomed.com.au.</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For further
information please contact: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prima BioMed Ltd: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stuart Roberts, Global Head of Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61
(0)&nbsp;447 247 909; <U>stuart.roberts@primabiomed.com.au</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australia Investor/Media: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr Matthew Gregorowski, Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)&nbsp;422 534 755;
mgregorowski@citadelmagnus.com </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Europe Investor/Media: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Axel M&uuml;hlhaus, edicto GmbH </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+49 (0)&nbsp;69
905505-52; amuehlhaus@edicto.de </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prima BioMed Ltd</B>,
Level 7, 151 Macquarie Street, Sydney NSW 2000 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Phone: +61 2 9276 1224 Fax: +61 2 8569 1880 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">www.primabiomed.com.au &nbsp;&nbsp;&nbsp;&nbsp;ABN: 90 009 237 889 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g18814img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g18814img001.jpg
M_]C_X``02D9)1@`!`0$$L`2P``#_X@Q824-#7U!23T9)3$4``0$```Q(3&EN
M;P(0``!M;G1R4D="(%A96B`'S@`"``D`!@`Q``!A8W-P35-&5`````!)14,@
M<U)'0@``````````````````]M8``0````#3+4A0("``````````````````
M`````````````````````````````````````````````!%C<')T```!4```
M`#-D97-C```!A````&QW='!T```!\````!1B:W!T```"!````!1R6%E:```"
M&````!1G6%E:```"+````!1B6%E:```"0````!1D;6YD```"5````'!D;61D
M```"Q````(AV=65D```#3````(9V:65W```#U````"1L=6UI```#^````!1M
M96%S```$#````"1T96-H```$,`````QR5%)#```$/```"`QG5%)#```$/```
M"`QB5%)#```$/```"`QT97AT`````$-O<'ER:6=H="`H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0``9&5S8P`````````2<U)'0B!)14,V,3DV
M-BTR+C$``````````````!)S4D="($E%0S8Q.38V+3(N,0``````````````
M````````````````````````````````````````````````````6%E:(```
M`````/-1``$````!%LQ865H@`````````````````````%A96B````````!O
MH@``./4```.06%E:(````````&*9``"WA0``&-I865H@````````)*````^$
M``"VSV1E<V,`````````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````
M````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````````````````````
M``````````````````````````````````!D97-C`````````"Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M('-21T(`````````
M`````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M
M('-21T(`````````````````````````````9&5S8P`````````L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``````````
M````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$``````````````````````````````````'9I97<``````!.D_@`47RX`
M$,\4``/MS``$$PL``UR>`````5A96B```````$P)5@!0````5Q_G;65A<P``
M```````!`````````````````````````H\````"<VEG(`````!#4E0@8W5R
M=@````````0`````!0`*``\`%``9`!X`(P`H`"T`,@`W`#L`0`!%`$H`3P!4
M`%D`7@!C`&@`;0!R`'<`?`"!`(8`BP"0`)4`F@"?`*0`J0"N`+(`MP"\`,$`
MQ@#+`-``U0#;`.``Y0#K`/``]@#[`0$!!P$-`1,!&0$?`24!*P$R`3@!/@%%
M`4P!4@%9`6`!9P%N`74!?`&#`8L!D@&:`:$!J0&Q`;D!P0')`=$!V0'A`>D!
M\@'Z`@,"#`(4`AT")@(O`C@"00)+`E0"70)G`G$">@*$`HX"F`*B`JP"M@+!
M`LL"U0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#6@-F`W(#?@.*`Y8#H@.N`[H#
MQP/3`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q!'X$C`2:!*@$M@3$!-,$X03P
M!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&
M609J!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E
M!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)
MN@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X`+F`NP
M"\@+X0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-#0TF#4`-6@UT#8X-J0W##=X-
M^`X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[!`)$"800Q!A
M$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3
M(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/`5$A4T%585>!6;%;T5X!8#
M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$`891B*&*\8U1CZ&2`9
M11EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H<`APJ'%(<>QRC
M',P<]1T>'4<=<!V9'<,=[!X6'D`>:AZ4'KX>Z1\3'SX?:1^4'[\?ZB`5($$@
M;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_`D'R1-
M)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$H
MHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV*VDKG2O1+`4L.2QN+*(LURT,
M+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C`U,&PPI##;,1(Q2C&",;HQ
M\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I
M-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\
M93RD/.,](CUA/:$]X#X@/F`^H#[@/R$_83^B/^)`(T!D0*9`YT$I06I!K$'N
M0C!"<D*U0O=#.D-]0\!$`T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(
M!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I-`DU*39--W$XE
M3FY.MT\`3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4
MVU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N5
M6^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB
M\&-#8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(
M:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R
M2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&
M>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$>`J($*@6N!S8(P@I*"
M](-7@[J$'82`A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6
MB_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4
M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY`
MGJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H
M4JC$J3>IJ:H<JH^K`JMUJ^FL7*S0K42MN*XMKJ&O%J^+L`"P=;#JL6"QUK)+
MLL*S.+.NM"6TG+43M8JV`;9YMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[I[PAO)N]
M%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8P]3$4<3.Q4O%R,9&QL/'0<>_
MR#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.ML\WS[C0.="ZT3S1OM(_TL'3
M1-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:^]N`W`7<BMT0W9;>'-ZB
MWRG?K^`VX+WA1.',XE/BV^-CX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI1NG0ZEOJ
MY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_\HSS&?.G]#3TPO50]=[V;?;[
M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____VP!#``,"`@,"`@,#
M`@,#`P,#!`<%!`0$!`D&!P4'"@D+"PH)"@H,#1$.#`P0#`H*#A0/$!$2$Q,3
M"PX4%A02%A$2$Q+_VP!#`0,#`P0$!`@%!0@2#`H,$A(2$A(2$A(2$A(2$A(2
M$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A+_P``1"`!]`L8#
M`2(``A$!`Q$!_\0`'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`
MM1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*Q
MP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA9
M6F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*S
MM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ
M_\0`'P$``P$!`0$!`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#
M!`<%!`0``0)W``$"`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1
M"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI
M:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ
MPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1
M`Q$`/P#]4Z***@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`***S?$7B'3O">AWVL>(;N&QTW38&GNKB
M5L+&BC))II`:$DBQ*6<A5'4DX`I0<@$=Z^6?@OX\U_\`:V\7:CXMN/M&E?"7
M0;HPZ#8QOY<FLW4;?-/.1R8U[)TSUSBN[^-O[3VA_!RZ32S;2ZOK;QB0VD3;
M%B4]"[=L^E9UJM.C'GF[([<OR[%9AB%A\+!RF^B_K1'M9.*:)4+E`R[P,[<\
MX^E?&&F_M_7XO1_;'A2U-H3_`,NUT0X'XC!KUKQ1J#?'#X<1^-/@?JK:?XOT
M>%Y-,E;/+CE[2>/.&5\;>>F017/AL=A\1*U.6IZF<<+9KE,%/%TK1?5--7[7
M6Q[OUI:\,_9:_:@TS]HGPY=QRVKZ/XM\/L(-=TB3.8),D;D)ZJ2#].E>Y$X&
M:[&CYX6BJIU2S#;?M=MN]/.7/\ZL!@1D$8(SG-%@'455_M6RS_Q]VO\`W^7_
M`!J=)%D4-&RLIZ$'(-(!]%0K>0/*8EFA,HZH'!8?A3IKB*W`,\D<88X&]@,G
MTYH`DHJ.6>.!-\\B1I_>=@!^=/!!&0<@T`+14<T\=NA>=TC4?Q.P`_,T0SQ7
M";[>1)4Z;D8,/S%`$E%%1S7$5LNZXECB4G&78*/UIH"2BJT>HVLKA8KFW=CT
M"RJ2?UJ:6:.!"TSI&HZLYP*&`^BF131SH'A=)$/1E;(--EN88"!-+'&6Z!G`
MS2`EHI`<]*9-<Q6X4SRQQ[C@;V`R?3F@"2BHY)XX4+S.D:#^)VP/SI7F2*,O
M(Z(@&2S-@#\::`?157^U;+_G\M?^_P`O^-/%[`T)E6:$Q#K)O&T?C1;4">BJ
MJ:G9R,%2ZMF8]`)5)/ZU:H:`****0!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`5
M\2_\%4_B5?\`A/X-:+X;TIC''XPU%X[UQWAA4/L_%BOY5]M5\B?\%+/@O??%
M#X(0:UH$4D^H>"+E[XP(N3);LH67`[D`*WT!JD"/1/V']*L=+_96^'\6DD&*
M?3C-(RGK*\C%\^^<C\*^<_VQ_AUK6C?$J^\2/;3SZ+JVPQW*J66-@H!1O3I7
M._\`!-W]KK2-`T6'X5_$.\ATX)<,WAZ\E.$D,C9,#'H#N)([<XK]'+NPMM0M
MVAOX(;F%QAHY4#J?P/%<F.P:Q5+D;L?1<,\0U<CQWUF$>9-6:[I]GT9^0:(T
MC!8D9W8A0JC))/;`K[__`&-OAOK/@/P%>S^)86M)=;NEN8;9^&CC"X!8=B>N
M*]DL_AYX7TZX^T6'A_1X)P<B2.R0,#]<5P'[2'[1GAK]G'P+<ZIKUU$VKW$#
MC2-,!S+=38P,+_<!QD^E<&7Y1]7J>TE*[Z'TW%GB!+.L)]4I4>2+:;N[MVVM
MV/A#1/%C_#;_`(*>:G%X?E,%AK7B![*]AB.$D69,L"!QP_/L17ZCZA_R#KG!
M/^I?!_`U^0?[#_@OQ+\?OVJXO'&L`W,&BZ@^KZU>GA1,VXQH/<MV]!7Z^:C_
M`,@ZZ_ZXO_Z":]L_.&?D3^RW^SY<?M/^,_B)9ZGXU\2Z'/H,IDLY+:Z=U+O*
MX^8%N@VCI7I/[)'Q6\=?#CX[>*_@KXJU^?Q1I%O;:A%%<23-*;>6"-B'C9N0
MI'!&>M>/_LP?!+Q[\:O'/Q`LOA7XZD\$_8YS_:#J\BFZ1I7`7Y"#Q@_G7W;^
MS[^Q-HG[.>F^(/$6I:M<>*/&&H:;/'-J4ZX6)2A+",')R3U).33`^'?V/O@`
M_P"T[K?C*U\0>./$VAG0T62WDMKQF#,[L/F#-T&*]4_8H\6>,_AE^UKK'PHD
M\47/C#PW%]IBN)C.\\2-$NY94+$[><*><5XI^R9^SGJ?[04_CZ#PWXLU+PS?
MZ-;B2!+4L$O'9FPDF"#CC'XU]`_\$MO$6DZ+XS\9^"M=T:QM?%]KOD74V3_2
M9XT?;)$Q/HW/%`,9\"]5OIO^"FGC&UFO[V2U634=MNUPYC7"KCY2<4?\%5?B
MUJ.D>+O`_ACP_>W-H^G1-JLYMY6C+.6VH#@\C"G@U5^`_P#RE`\9_P#734O_
M`$%:IW'AJ;]J3XX?M$>(+RU6]L?#?A^XTW1V9=PCDC^YL_VOW;'CUH`Z+]N?
M]H)]:_94^&,6E7ES:ZGXTB@OIFMY3&P6&/#9(.?OG]*^OOV4O'LGQ(_9\\$Z
M[>.9+N?3$BN6)R3)'\C9_*OS8_9-\+ZE^TWXST?0?%EHMQHGPS\*WD%NNW*^
M;(6\K?GJ=[?^.U]3_P#!,[XA>5\'_%GA376,$W@+59S(&XV0-EC^15J`9A?\
M%(OB!KOB;Q+X(^#OPXNIEU?Q!<K<7<5M*4<DG;"I8<@?>8^PJ/\`X)G?$35-
M&U?QS\)O'-U+)JV@WK7%M]HE9W)5MDR@L<D`J#^->`>&OCAK'C+]L#6OB_8^
M!M?\:V.D7,D-A::7&3Y"JICA+-@X^4%L>IJKXN^->H>$OVO]`^+>H>"-?^']
MA?W47]H6E[$5-RN-D[C@!LJ02/44`?L)7Q7_`,%4]1N],^!NAR:==75I(==0
M%[>9HR1Y;<$J1Q7V1I&J6VMZ9:ZAIDHGM+Z%)X)%Z.C`%2/P-?&'_!5\@?`C
M0R?^@\G_`*+:I6XD?,GC?]F\>"?V7-!^+FC_`!0UZWUN[M(+IM+GOV`D=VQM
MB(;=D=>1VKVW6OB;XJ^('_!,R^\0>,+V[?6`P@2_#&*2>))0%?(P<XXSWQ7G
M&I?L7>'+7]DS2/BK9^+=3M=:MM(BU,6FK3K)8N^?]4J'IGH!ZUU^I?&?4/C/
M_P`$WO%-YKUC8V5YHUU'8-]AMA;P2*KJ5*H.!P><=ZH9WWP7^-T_P6_X)WV?
MC.>4WNJ6R3Q6/VN0R>9</,53<3R0.OT%>;_";]COXA?M0^$&^)7Q5^)FOZ/J
M7B56N-,M;61]J+D[&90P"H<<*HZ5A^*?#U[K?_!+/P_<:<&=-)U;[5<J/^>8
MG=23]"PK[G_9&\4:;XL_9S\!W>A3)-#!I$-K*$/^KEC&UT/H010!\W_L=?%K
MQU\-?CCK'P"^,^IMK+Z=$[Z-J,S%I&"C>`&/+(R<C/((KS?_`(*C_%S4;'XK
M^#_#NB:C=6T6@V@U"XCMYV3=*[C;NP>?E7H?6NHDNX/B#_P5+ANO#$R2VOA>
MR(U*=#\JF*!@X)]BP%><V/PINOVMOB%^T1XUOI//MM'MI[31G)X$T;9C`]@D
M1_[ZH`[_`/X*%?M%2WGP-^&NE>%;NX@D\96L.KW,L,I1A%&JE5R#GER?RKV3
MXG^/V\<?\$\+OQ+I\\\,]WX4@+2)(5=9$*HYW#G.5-?&W[)7@?6?VHO&T*^+
MX5F\/?#?PA-IT889"NZ2"$8/\6YB?^`UZG\,/&:ZU_P3C^)GA>=LW_@F2XL9
MD/4(TH9#_P"A#\*`,/\`92_8TTOX_?!ZS\7>)/B-XNTJ]N+R:!K:WOLH`A`!
M^9L\YKZ)^-7PKB^`G["GC3PWH&OZMJZ6D+3Q:E=3GSR9)T)&X'H.G6OG[]CS
M]A[PY\=/@E8^*M;\5^,-)N[B]GA-MIMZ(X0$(`(7'4YKZ9_:>\!6WPP_86\3
M^%=,O+W4+71-)2".YO9-\T@\]3ESW/-`=3Y3_9D_8MN?VA/@7'XQM_B-XIT3
M7YKN>"",7#O`IC("D_-NYSSBNG_9]^/7Q-_9O_:&L_@S\>-3FUG1[ZY2TM+N
MY8RM&TG$,L<AY,;'`(/3->Y_\$TKB*S_`&3[*>[DCAABU2]:221@JJH89))Z
M"OFCX[>.M/\`VC?V^/`5E\,-FI0^'KRTM9+V'E)_)F,LL@/=5&1GVH`_4VBD
MI:S$%%%%`!1110`F:6OD31OV^868#7_"4J>K6EX&_1A78Z=^W%X$N=HOK37+
M-CU!MU<#\0:X(YI@Y?;1]-6X.SREOAV_2S_)L^BJ*\7LOVOOAE=D!M8N;<G_
M`)[6;C'Y`UUFD_';P!K8']G^+-%8G^%[@1G\FQ71'%T);37WH\RKDN8TG:="
M:_[=?^1WE%8D?C?P],H:/7=&8'IB^CY_6IX?%&C7#;8-6TR1O1+M&/Z&M5.+
MV9PO#U5O%_<:E%1QSQS+NB=77U4YI^X9[U1D+12$@49%`"T4F:6@`HHHH`**
M**8!1112`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`IDT23Q/',BR1NI5D89#`
M]01Z4^B@#\H?VW?V%]8^&FO:AX\^$=E/?^%+J5KJ\L[89ETE\[F8`<F+/((^
M[6S^Q[_P43UCPU<:7X)^,:7NO:;,R6VFZI;H9KR-V8*J2#/SK[CGZU^H,\"7
M,3Q3JLD4BE71AD.IX(([BORG_;BM/A]^S]\4KN#X(Z>EAXSUJS!O_*53;Z.K
M=6MUZI._<C[HZ8S5H=SZH_:3_P""A?@CX/6%UI?@B>#Q7XOV82V@)-O:-T_?
M..X_NCGZ5^='A[PS\4?VW/BW),S7FKWUU/NN[V4D6FEPDY('9%`Z*.3BO+;#
M2%LO$^FP_$*VU?3=/NKF-[YW@:*?R&8;Y$#CDX).:_=OX'?#GP3\.?A[I=I\
M)+*SM]$NK:*:.YA`+W@*C$DC_P`3$'O0&Q5_9_\`@+X>_9Z\`6GAGPI&)'4;
M[Z_=`);V;N[$?D!V%>D7$/VBWEB)(\Q"N?3(Q4E%)"/GO]F?]D33_P!F[Q+X
MIU?3/$%[K+^*"IDCN+=8Q#AV;@CK]ZO>M2L_[0T^YM2Q1;F%XBPZC<",_K5J
MBF!\[?LM?L>:=^S%JOB*^TOQ%?:X_B!45TN+=(Q%M8GC;UZU53]BW2M._:7'
MQ@\-^(+W2KJ2X\ZYTF&W00S$ILD!/7YNI]Z^DZ*`/FKPY^QA:>&/V@?$?Q5T
MWQ5J`U+7XKM5M&MDV6[3J%W`]3MQD5U7[-7[,NG_`+.OA_Q!I\.L77B&X\27
M[7E[=74*HS$KC;@=1R?SKVNB@#Q;]GG]E_0OV=M0\7W?AR]N+U_%FHFZ831J
MOV9,L1$N.H!8]:XRP_8JA\/W_P`4[CPEXQU/25^*"%)TCMD/V`,Y9_+/?(+#
MGUKZ<HHN!XY^S'^S;I'[,W@BYT#0[V;59[Z\:YNK^>())*>BJ0.P%5?VI?V7
M-&_:A\+Z;I6N:C<Z/<Z3=&>UO;>-78!AAE(/8C'Y5[;10!R'PE\"3?#+X=Z'
MX6N=5FUHZ):BVCO9HPCR(OW<@<9`P/PKB?VHOV<+/]IKP39>'=4UBZT6.ROE
MNQ/;PK(6(4C;@_6O9:*`/A5?^"6MC=V5OINM_%7QE>:/;@!;#"B(`=`%)P/R
MKW+6OV1/"\O[.MS\(?"MS=:+I%P`7O0HEF>3=N+MG@DD5[Q11<#R7X6_L[:)
M\/O@9'\+]7F?Q%HOD30W#W400S+(Q)R!TQGCZ5\NZE_P3G^('@W4KNU^!/Q>
MU+P]X8OY"SZ?-+*C1`]1\APWUX-??E%%P/G/X`_L::+\"_"FOQ6VJW.J^+O$
M]I)!?^(9TS*F]2"(P>@R=W/)-=%^S;^S+IG[.O@/5O#5EJEUKG]M7DES=W=U
M$J.^]=NW`]!G\Z]JHH`\7_9N_9BT3]FW2_$=IH%]<ZHWB/46NYI;B-5*)R%B
M&.P!/YUP6A?L)Z7X?\/_`!4T:Q\4ZD+'XGL7F0VZ?Z"WF%\I_>ZD<U]2T4`?
M"^C_`/!,:7P_8K9Z%\8O&NFVBDLL%J!$@)ZG:&QDU[7:?LKD?LWZM\)M9\8:
MSJZZJTADUJ\`DN%#2!\8)((&,5[[11<#X3TS_@EQ!I^G_P!EI\6?&4.D.3YE
ME;*L<;9Z_*#CFO>OV>OV/?`'[./GW/A*UGU#6K@;9-5U`B295QRJ8&$![XKW
M*B@`HHHJ0"BBBD`4444`?D)CM2@5]'7_`.PKXWML_8=7\/72CIF22+^:FN/U
MO]E'XF:)G_B0+J*C^.QN5ES^!P?TKX*>7XJ.]-G]-4.*,FK?!B8W\W;\['D6
M*5%&2,5U>H?"7QMI)(U'PGKT!'7=9.?U`-<_>:5>Z8VW4;.[M&])X&3'YBN6
M5.<=TT>K1Q5"LKTYI^C3_4@"CT%6+._N=-D\RPGEMW_O1L5-51(IZ,OYU(OJ
M"*E.S-9)25I+0Z_2_B[XVTD#^S/%.M0`'A1=,P_(UU-E^U!\3;`*!XFFG`[3
MV\;_`*[:\H%+6\<36C\,W]YYE;*,OJOWZ$'_`-NK_(]TL_VQOB/;%?/N=)N@
M.HDL0,_B"*ZO3/VYO$,**-6\.:5<D=6AF>,G^8KYE`R*>G45O#,\7':;/,J\
M)9+4^+#Q^5U^3/K^Q_;KL7`_M#PG>(>YAO%8?J!6U9?MN^$;E@+W2-?MAW(2
M.0?HU?%7`H7WKHCG.+7VE]QYM7@#)9K2#7I)_K<_0#3?VL_AQ?(N_5+JT8_P
MW%FZX_$`BNCL_C]\/KY0;?Q5I63V>0I_,"OSB`R../>I44=P*VCGV(6\4SS*
MOAOEK^"I-?<_T/TRL?B;X3U%@+/Q)H<K'H%OH\_SK;AU6TN4W6UU:RKV*3*P
M_0U^680!AA1^568+F:%CY,TT?^[(16\>(9=:?X_\`\ZIX:4_L8E_./\`P4?J
M4LN\90J?H<U)GUK\Q;7Q-K-H0;76-6BQTV7LB_UKHM-^+WC726!L_%&L@#M)
M<F3_`-"S6JXAI]:;^\X*OAOB5_#KI^J:_P`S]&*6O@VQ_:=^(MF@4:W'.!WG
MLXV/YXK:M?VM/'T?^M?2)_\`?L\?R(K=9]A7NFOE_P`$\ZIX?YK#9P?S?^1]
ML45\@V/[9'B>,C[?HVC7"CJ8V>,G]372V'[9L14?VGX9G![FWNP1_P"/"MXY
MQ@Y?:_`X*O!F<0VI7]&O\SZ9HKY^@_;$\.N/](T76HL_W3&^/UK5M/VL_!4^
M/M$6N6Y/7=:!A^C5M',L(_\`EXCBGPUFT=Z$OS_(]LHKS"P_:.\!7Q'_`!.C
M;D]I[=T_I6[;?&#P7=@&#Q/I!]FN`I_6MUB:#VFOO1Q5,KQU/XJ,E_VZ_P#(
M[*BL"W\>^&[S'V77M)DSZ7:?XUI1:Q8W`'V:]M9<]TF5OZUHIQ>S1RRH58_%
M%KY%VBF+(&'RLI_&G`YJC(6BFLV/\:7--@+1112`***3.*`%HI,YI:`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`0U^8EI^S[)\5_^"COBS3/B
MD)9-.L9FUM86X%[;KL\A1_L<@'_=Q7Z>5RGB'X=Z;KOB?2O$L2_8O$.C!TMK
M^!0'>%_OPR<?/&<`X/0@$8-4F!\H_P#!3;X(:'XA^#1\=6UK%;Z_X3:&%)T.
MWS;1GVF(CH<%@1^->\_LAZ;J&D?LU?#ZTUZ*6"]BT:+S(Y5PR@Y*@CM\I%=C
MX\^&NE_$J.PM/&*?;M(L;N*\.G$8CN)XSF,R?WE4\[>A(&:ZV-!&H5`%51@*
M!@`>@IM@.HHHJ4`44450!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%)03CK4L!:*3-(3SQ2`=135?/M]:*>@#J:R!A@@$
M4ZB@!NP=N*KW6EV=^I6^M;>Y!ZB:(/\`S%6J*3U&FT[HY;4?A9X/U<$:CX9T
M.?(Y+629_,"N+UO]E;X::SDGP\MBYZM93O'^F2/TKUVBL9X:C/XH)_([J&:X
MZA_"K2CZ2:_4^=+W]A[P1<`FQO\`7K,GI^_63'YK7*ZQ^P=%ACH/BN53_"MW
M:`C\2I_I7UK17-+*\)+[!Z]'C'.Z3TQ#?K9_FF?#-]^Q)XWMW866HZ'>*O0B
M5HR?S%<YJ7[*'Q*TL,5T:"\`[V]VC$_AD5^A&T9I"@/6N:>185O2Z^9ZM'Q$
MSB'Q\LO5?Y-'YD:E\)_&>D.5U'PQK41'<6C./S7(K"GT/4;+/VW3[Z`@\^;;
MLN/S%?JH$`&.:BGL;>Y!%S!#*#U#QAA^M<T^'X/X:GX'J4?$S$+^)AT_1M?G
M<_*@L4.&P/8U(IQWK].+[X=^%]2S]N\/:-,3W:RCS^>*P-2^`'P^U2-DG\+Z
M:A;^*%#&P_$&N>7#]5?#-'HTO$K"/XZ$EZ-/_(_.E.M2+UK[@U/]CWP#>$FS
M75K$GH(;O<!^#`USUS^Q/H,N?L?B#5H,=`\*/_45RRR3%K9)_,].EQ_DTU[S
ME'UC_E<^1EZ8J2OH[5OV*M5@W'0_$-E<#LMS"T9_3-<W>?LD>/;8GR4TJY`Z
M&.ZQG\P*YY97BX[TV>A2XKR:JKQKI>NGYGC4?45(@Y.>E>BWW[.?Q!TS)DT%
MYE49/D3+)^@-<Q?>`O$FF$_VCH.K08/):V8_R%<T\-6A\46OD=]+,L%6_AU8
MR]&F8L?2I,\`U(]A=6P/GVMS%C_GI$R_TIAP%`/&*Q>AT73U1(G3/M4HZ`U$
MA&,`U,/NT7N)CT/`%2H.0*B7MZU*A^:J,GIJ31Q(6^ZOY5:BD>(`Q2.A_P!E
MB*KH<,:D4Y.*/0RGJ:5KK6HP']SJ%]'Z;;AA_6M2V\:>((>(M<U9,>EV_P#C
M6!'T%31]<UI&<TM&<KP]&:]Z"?R1V5G\5O&%F1Y/B+4B!V>0./U%;MI\>/&U
MO]_54EQ_SUMD/]!7FP(S5E#SU[5O'%UUM-_><-3*L#/>C'_P%'JMO^T9XNCQ
MYK:=*/>VQ_(UH0_M*>)`1OLM+?\`X`P_K7CJMCIVJ=&.:WAF.*7VV<,\@RR7
M_+A?D>W6O[2^J`_Z5HUE(.^R5E_G6M;?M+1-C[5H<JYZE+@'^8KP2([EY.,=
MJGC.16T<TQ:?Q?@CDGPQE37\+\7_`)GT/!^T9H\H_?:;J,9]BI_K5R']H#P\
M_P!^'44_[8@_UKYQC8\Y[5.C<#I6ZS?$+3]#C?"66OHU\SZ2@^.OAB0_/)?1
MY_O6QJ_%\8O"TPXU'9_OQ,/Z5\QK)ZT\L.YK99O7ZI'/+@_!/:4E\U_D?5$/
MQ+\,3_<UBS'^\V*N1>-M`F&8]8T\CWG45\DLX';-1N=PZ_I5_P!LU%O%&,N"
M\._AJ-?<?8*>)](D_P!7J=@WTN%_QJ=-;T]QE+ZS;Z3K_C7Q@ZCG'3ZU%Z]1
MCWI_VXU]@R?!4.E;\/\`@GVRE_;2?ZNX@;Z2`_UJ42JWW65OH:^'C<RQC]W-
M,G^[(P_K0-9U"+B+4+Y0.FVY<?UH6?+K3_$G_4>3VK?^2_\`!/N/-&1FOA[_
M`(2O6H^$U?4Q_P!O;_XTB^./$2'Y-<U5<?\`3TW^-/\`MZ'6#)_U%K]*R^YG
MW%FC-?#[?$;Q5%_J_$6K#_MX)J2/XM>,HAA?$>I<>L@/]*O^WJ/\C)_U$Q?2
MK'\3[<S1N^M?%(^-GC>W(V:_<G_>13_2ID_:"\<P<#5T;_?MT/\`2G_;V'_E
M9E+@;,%M.+^;_P`C[/WCU%`8'H:^-D_:4\<Q'F\L9,_W[1:F3]J;QM&/^84_
M^];'_&K6>87S^XC_`%&S3^[]_P#P#[$S2U\@#]K'QB@^:UT9_P#M@P_]FI5_
M:X\7<9T_1L?[C_XTUG>%[O[B?]1\V[1^\^OJ*^03^U[XK7KIFCG_`("_^-.'
M[8?B<=='T<_BX_K3_MO"=W]Q/^I.;_R+_P`"1]>45\B#]LGQ&.NB:0?I(]!_
M;,\1#_F!:0?^VKBA9U@W]I_<P_U(SG_GVO\`P)?YGUW17R'_`,-H>(5Y;P_I
M./\`KO)2']M;7A_S+FE?^!+_`.%/^V<'_-^##_4C.?\`GVO_``*/^9]>T5\@
M?\-L:_\`]"WI7_@2_P#A2']MO7Q_S+>D_P#@2_\`A1_;6#_F_!C_`-1\Z_Y]
MK_P*/^9]@45\=G]MWQ`#QX;T@CWN9/\`"F2?MO\`B(#Y?#FCC_MXD/\`2C^V
M<'_-^#'_`*C9U_S[7_@4?\S['HKXR_X;A\2_]"[H_P#W^DJ)_P!N'Q2#\N@:
M*/3,DE+^VL'_`#/[F4N`\[_Y]K_P*/\`F?:5%?$[_MO^+N<:)HB^VYS_`%J"
M3]MWQH3\FDZ"O']US_6AYUA%U?W%K@'.G]B/_@2/M^D)`ZFOAJ3]MOQSGY+#
M0%_[8N?_`&:JLW[:WC^3_5P:%%]+5C_-JC^W,)Y_<:KP\SI](_\`@7_`/N[S
M%]>M&\5\`7/[8?Q(EXBO-*BS_<LA_6LJZ_:L^)UT?^0_'%_URM$']*3SW#=$
MS:'AQG#>K@OF_P#(_10-GI_*E)P*_-:Y_:-^)5P#YGBW4%S_`,\U1?Y"LR?X
MW_$&Y_UWC'7C]+G;_*LWQ!16T7^!UP\,LP?Q5H+[_P#(_3S-)N]C7Y:3_%CQ
MK<?Z[Q7K[?\`;\X_D:HR>/?$TYQ/XCUU@>N=1E_^*K-\0T^D']YO#POQ3^+$
M1^YO]4?JG+?VT'^ON((_]^0#^=4IO%>BVX/VC5],CQUW7:#^M?E+<ZUJ-YG[
M9J.H3Y_YZ73M_,U3;+??+,3W))K-\0]J?X_\`ZX>%O\`/B?NC_P3]5;GXG>$
M;,$W/B;0H\=<W\?^-8&H?M"_#K30?M/B[1^.T<OF'_QW-?F.4'<`X]:-H7D`
M?E6<N(*K6D%^)W4O"[!I^_7D_1)?YGZ':C^V1\,;#.S5KR[(_P"?>QD;/Y@5
M@W?[='@"+/V6TUZY(]+0)_,U\''I46:QEGN*>UE\CT:7AID\5[SF_FOT2/M;
M4?V^]#B!&D>%]4G;MY]RD8/Y9KC-4_;X\2S,1HWAG1[9>QN)Y)#^F*^7>Q([
M4GUK"6;XR7V[?<>E0X#R&G_RXN_.4O\`.Q[_`*A^V[\1[M2+7^PK+/\`SSLR
MV/\`OIJXW7/VF/B9X@R+OQ5>VZ8^Y9HD`_\`'1G]:\RI.IK">-Q,]ZC^\]6A
MPUE-!^YAH?\`@*?YF[>>/?$^HOOOO$>N7#9S^\OY#_6BL.BN9SD^IZT<'AXJ
MR@E\D?L'1117Z,?R.%%%%`!1110`4444`%%%%`!1110`4444`%)BEHIW`;M'
MI2XI:*`$Q05!'(S]:6BBX%:73K6<8FMK>0'LT0/]*Q[_`.'OAG4R3?:#I4Q/
M4M:KG^5=#14N,7NC2%:I!WC)KT9P-Y\"O`MZI$GARQ0GO&"G\C7/:A^RWX'O
M1_H]M?6;>L5QQ^1KU^BN>6#P\MX+[CNI9QF%/X*\E\V?/US^Q_HA8FQUO4XL
M]!(BL!61>?L?RKDZ=XB0GL)K?_`U],4E8/*<&U\'YGH4N*\WI[5K^J3_`$/D
MC4/V5/%=LQ^P76F7B]OWAC/ZUCS?LZ>.[7_F&0RX_P">=RAS^M?9Y'OBDV^Y
MK!Y'A6M+KYG=#CC-(_%ROY?Y,^';SX0^,M/S]HT"^P.\:;_Y5BSZ!JE@2M]I
MM_`0<'=;O_A7WV5)[X%(T*N,.J-_O+FL)9!2^S-G;2X]Q"TG13]&U_F?G\T+
MQ<R1RK_O1D4]6'J.E?>DNAZ?<?\`'Q8V<F>NZ!3_`$K*O/AYX:OB3<Z)IK$_
M],`/Y5@\@GTG^!V0X[I/XZ+^37^2/B>,CBIDXZ5]>S?!;P;/G?HELI/]QF7^
M1K)O/V>/"-R#Y$%U:D_\\YS_`%K*61XA/1K^OD=$>-<!+>,E\E_F?+L;8P:G
M#DD=L5]`W'[,>DL<VFKW\/H&16K/F_9C(/\`H^N\?[=O_@:AY5BE]F_S.J/%
M.5S7\1KU3/%HY,\]ZD609'K7J-W^SCK$)/V+4K&?T#`IFL>Y^!GBVW;Y+6VF
M]TN!_6LY8#$QW@SHIYYEL]JR^>GYG$[CFG!\]JZ:;X3^+H#SH\[8_NNI_K6=
M=^"_$-@,W6CWZ`=2(B1^E8NC66\7]QUPQ^$G\-2+^:,EI">F*:SX7FG3VMW;
MG%Q;7$6/[T9']*K2-\OS;OQ&*R:?4Z5*+V=R1G&#Z5`SYSCM3#*"/05&\F.G
M-2]C11!W.,5"S4\L`/6H'?`Z=ZA^1HE9#"V3S44G4XIS<@U$YQ4,TB1MUJ%C
M@YIS\'.3S3'Z4C=$,KG/2HG^;KQ4C<U"S>U04D[W(I.N*@;M4S$$C%0MW-,U
M6HU^]0'H:>QXZTP]*AO4T2(SQP*C<X]*D?[I^E0C!%+<UV&_2HV.2:<YZ5&Q
MY`H-$1R'`]1452R=,5$>M,N.C(W[4Q^AR:>QID@XS3-41-C'>HSC/-.<9(IK
MKU^E,L8_09JNYXJ=^@^M0L,@BE8I(:!D#%(<BG`;1S3&Z\4,UZ#&J$]:F;K3
M$ZFA#&9Q29R>13GX:DIEH:1FD_I3B<4S'S$^M)C(SUHH/6BD-#6ZTE*W6DH*
M`]*1NE*>E(W2@J(T]*BJ4]*BJC5!FBBB@89Q1UH/2B@74****!G[!T445^D'
M\?A1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`-VTN*6BF`W:._-!7(P:=10!$]I#
M(,211.#V9`:J3>'],N,^=I]E)G^]`I_I6A14N*?0J,Y1V9SMW\/?#=\I%SHV
MGMGKB$#^59-Q\%O!]QUT>%">Z,17<45FZ%*6\5]QT0QV*A\-22^;/-KKX`>$
M;@?+:W,7NEP>*Q;W]F3P_.I^QW^I6Y/(RP<?J*]CHK&6`PLMX([*>>YE3^&M
M+[[_`)G@-U^RLC?\>OB"11Z/;`_UK-N?V5M3Q_H^NV3?[UNPS^M?2%%8RRG"
M27P_BSLAQ7FT?^7M_5+_`"/E6\_9?\4QY^R7>F38Z#S"O\Q7/7W[/WCFW)":
M9'.!WBN%.?SK[*Q1@=A6+R3"MZ77S.RGQKF4=^5_+_)GP]/\&/&UOGS/#]Z0
M/[NUOY&LJ]^&_BFT'[_P_JJXZXMR?Y5][8HQSVQ6+X?H])L[8<>XM?%2B_O1
M^=EWH6IV/_'WIU_`!UWVS#^E9S#82)`RD=F4BOT?EM8IN)8HW'HR@U2G\-:5
M<G_2-,T^3_>ME/\`2L7P_P!JGX'=3\0;?%A_NE_P#\YG8>HQ41D4G[PY]Z_0
M^X^'GAFYSY^@:4Y/K:K_`(5D7GP6\$WQ)F\-:<#ZK'M_E6,N'JO2:.V'B#A/
MM49+YI_Y'P*S`@X(J$C;UK[FN?V:?`%P21HOED_W)W']:S9OV4O`LV=L&HQ$
M_P!R[/%8RR'$K9K[_P#@'9#C[+&_>C)?)?YGQ0XZ5&>M?8M[^QYX5GS]DU#5
M[?T'F*_\Q6%>_L6VC%C8>);J/T$MLK?RK&62XQ+X5]YW4N.,GD]9M>L7^ESY
M2D8$XJ(G'6OI>Y_8HU,D_9O$UDWIYEJP_D:S+C]B[Q0I_<:WHT@]65U_I6?]
MDXQ?8_([H<6Y++_E^ON?^1\\/R,U"W>O>;W]COQQ;Y^SSZ-=>FRX*_S%<]??
MLM_$>T)VZ-%<`?\`/&[0_P!:Q>`Q4=Z;.ZEQ)E,]%B(_?_G8\D;@Y--8YS7H
M%W^S_P#$2USYOA34B/\`8*-_(UEW'PC\;6W^O\+:TOTMBW\JS^KUEO!_<SNI
MYI@9?#7B_P#MY?YG',0<8[&HCUKH;KP!XGM!FX\/:U&,_P`5D_\`A6/<:3?V
MA/VNQOH?^NENR_TJ'"2W1W4\31EM-?>BFXST%1GCK4K,$^_E?]X8J%W4CAE_
M.H:-TT]4(3FF*0"<TXL!U(J/J30B[`YR:*0C'7UH8XIE)"$\]*C?@T\L.YJ-
MV!QBDQB4A.!S1F@]*0T-)STHH^E%!0'I2-THSGI3<GO32*30'I452GH:BZ=:
M9J@HHHH"Z`]**".#10,****`/V#HHHK](/X_"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"D-+10`W%!3/.3FG44`,*9'-03:;;7`(GMX)`>S1@U:H
MHT&FUL8EQX,T*ZS]JT329L_W[.-OYBLRX^$W@VZ/[_POH3$_].*#^0KKJ*AT
MX/=(WCB\1'X:C7S9P4WP'^'UR<S>$=$/TMP/Y5F7?[,WPUO"2WA6PB)_YY%D
M_D:]0HK-X6@]X+[D=$,VS"'PUYK_`+>?^9XO=?L@_#*Y)(T>YAS_`,\KV1?Z
MUFS?L6?#E\^3#J\1]KYC_.O>J*AX'#/_`)=K[CJAQ'F\-L3/_P`"9\ZS?L/>
M!I"3'>Z[%Z8N%./S6LNY_8/\+R$_9?$&MQ>FY4;^E?3U%9O+,(_^7:.F'%^>
M0VQ,OP?YH^2;S]@6T8G^SO&%TOH)K%3C\FK#NOV"-:7/V/Q7ISCMYEHZY_(U
M]I45F\HP;^Q^+.N''6?1_P"7]_\`MV/^1\,R?L(>+U)\K7M!D';*R+_2J4_[
M#?CV/_4WN@3?]MW7^:U]Y$9I:S>281]']YU1\0\\2LY1?_;J/S[N?V*_B3`/
MW,.BSG_9O\?S6L:[_9'^*-K_`,P"&<?],;V,_P`R*_1S%&*AY%A7LW]__`.J
MGXE9Q'>,'\G^C/S(O/V<?B;9EO,\&ZJP7J8@L@_0UD7/P6\?VIQ/X,\1@#^[
M8L?Y5^IV!1CZUF\@H=)/\#JCXH9C]JC!_P#@2_5GY13?#'QC;9,_A7Q!&/\`
M:T^3_"J$WA#Q!;G]_H>KQ_[UA)_A7ZUL..IIB_/]X"H_U>A_._N.F/BEB/M8
M9/\`[>?^1^1<VEWT`_TBQO8O4O;NO\Q5-W$9Q)\I]&XK]?I+&WE_UL$+_P"]
M&#5*?POHUV"+O2=-FS_?M$;^E9OAY]*GX?\`!.NGXJI+WL+]TO\`[4_(SST[
MNG_?0HK]7+GX4>#+QMUSX6T&1O4V$?\`A14_ZO5/^?B^XZ%XJT.N&?\`X$O\
#C__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
